4/A: J&J Amends CVRx Insider Sale, Discloses Additional Shares

Johnson & Johnson filed an amended Form 4 to disclose an additional sale of CVRx, Inc. common stock that was previously omitted.

Summary

• Johnson & Johnson, a 10% owner and director of CVRx, Inc., filed an amended Form 4 to correct an administrative oversight.
• The amendment discloses an additional sale of 16,000 shares of CVRx common stock on November 25, 2025, at a weighted average price of $10.03 per share (ranging from $10.00 to $10.22).
• An earlier reported sale on November 26, 2025, involved 6,337 shares at a weighted average price of $10.03 per share (ranging from $10.00 to $10.23).
• Following these transactions, Johnson & Johnson, through its wholly-owned subsidiary Johnson & Johnson Innovation JJDC, Inc., indirectly beneficially owns 4,024,861 shares of CVRx, Inc. common stock.

Sentiment

Score: 4

Explanation: The sale of shares by a significant institutional investor and director, Johnson & Johnson, is generally viewed negatively by the market as it reduces their stake and could imply a lack of conviction or a strategic divestment. The administrative oversight requiring an amendment also adds a minor negative note regarding internal controls.

Negatives

• A significant 10% owner and director, Johnson & Johnson, sold a total of 22,337 shares of CVRx, Inc. common stock.
• The sales occurred at a weighted average price of $10.03 per share.
• The need for an amendment due to an administrative oversight indicates a potential lapse in internal reporting controls.

Risks

• The sale of shares by a major institutional investor and director could signal a reduction in confidence or a strategic portfolio adjustment, potentially impacting investor sentiment.
• Administrative oversight in reporting transactions could lead to questions regarding the accuracy and timeliness of future disclosures.

Future Outlook

NA

Management Comments

• The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

This filing reflects a routine disclosure of insider trading activity by a major institutional investor in the medical device sector. While the sale itself is specific to CVRx, Inc., large institutional sales can sometimes be interpreted by the market as a signal, though the specific reasons for such sales (e.g., portfolio rebalancing, strategic shift) are not disclosed in a Form 4/A.

Related Party Transactions

• The reported sales are by Johnson & Johnson, a 10% owner and director of CVRx, Inc., through its wholly-owned subsidiary Johnson & Johnson Innovation JJDC, Inc. This constitutes an insider transaction.

Stakeholder Impact

• Shareholders: May interpret the sale by a major institutional investor as a negative signal, potentially leading to downward pressure on the stock price.
• Management: Could face questions regarding the reasons for the insider sale and the administrative oversight in reporting.

Next Steps

• Johnson & Johnson undertakes to provide detailed information on share sales at specific prices upon request.

Key Dates

Recommendation

While the sale of shares by a significant institutional investor like Johnson & Johnson is generally a negative signal, the amount sold (22,337 shares) is relatively small compared to their remaining beneficial ownership of over 4 million shares. The sale price of $10.03 is also a specific data point. Without further context on CVRx's operational performance or J&J's strategic rationale for the divestment, a 'hold' recommendation is prudent. Investors should monitor future insider activity and CVRx's financial reports for more comprehensive insights before making a 'buy' or 'sell' decision.

Keywords

CVRx, CVRX, Johnson & Johnson, JJDC, Insider Sale, Form 4/A, SEC Filing, Stock Transaction, Beneficial Ownership, Medical Devices